Partha Basu (France)
International Agency for Research on Cancer Early Detection and Prevention
Presenter of 1 Presentation
EFFICACY OF A SINGLE DOSE OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE- FINDINGS FROM THE INDIAN COHORT STUDY (ID 900)
Session Time
12:35 - 14:05
Session Type
Clinical Science Oral Session
Lecture Time
12:35 - 12:50
[{"name":"EFFICACY OF A SINGLE DOSE OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE- FINDINGS FROM THE INDIAN COHORT STUDY \u003Csmall\u003E(ID 900)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":900,"presentation":"EFFICACY OF A SINGLE DOSE OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE- FINDINGS FROM THE INDIAN COHORT STUDY \u003Csmall\u003E(ID 900)\u003C\/small\u003E","session":"Oral Session 10: Vaccines Clinical Aspects","presenter":"Partha Basu (France)","photo":""},"playlist":[{"name":"EFFICACY OF A SINGLE DOSE OF HUMAN PAPILLOMAVIRUS (HPV) VACCINE- FINDINGS FROM THE INDIAN COHORT STU","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation id 900.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation id 900.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/C4A004B2.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/83\/Presentation id 900.vtt"}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"7E22UU0gw"}
[session]
[presentation]
[presenter]
Moderator of 1 Session
Session Type
Public Health Oral Session
Session Time
13:15 - 14:55
[{"name":"EVALUATING THE REACH AND EFFECTIVENESS OF A COMMUNITY-BASED HPV-SCREENING STRATEGY \u003Csmall\u003E(ID 235)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":235,"presentation":"EVALUATING THE REACH AND EFFECTIVENESS OF A COMMUNITY-BASED HPV-SCREENING STRATEGY \u003Csmall\u003E(ID 235)\u003C\/small\u003E","session":"Oral Session 8: SCREENING IV. Implementation, dissemination, and communication\u00a0","presenter":"Megan J. Huchko (United States of America)","photo":""},"playlist":[{"name":"EVALUATING THE REACH AND EFFECTIVENESS OF A COMMUNITY-BASED HPV-SCREENING STRATEGY","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/235.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/70\/235.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/44292D51.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/235.vtt"}]},{"name":"CESTAP: THE PILOT OF THE CERVICAL CANCER SCREEN AND TREAT ALGORITHMS STUDY USING HPV TESTING IN AFRICA \u003Csmall\u003E(ID 870)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":870,"presentation":"CESTAP: THE PILOT OF THE CERVICAL CANCER SCREEN AND TREAT ALGORITHMS STUDY USING HPV TESTING IN AFRICA \u003Csmall\u003E(ID 870)\u003C\/small\u003E","session":"Oral Session 8: SCREENING IV. Implementation, dissemination, and communication\u00a0","presenter":"Mathilde FORESTIER (France)","photo":""},"playlist":[{"name":"CESTAP: THE PILOT OF THE CERVICAL CANCER SCREEN AND TREAT ALGORITHMS STUDY USING HPV TESTING IN AFRI","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/870.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/70\/870.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/B328BF79.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/870.vtt"}]},{"name":"INTRODUCING MOBILE COLPOSCOPY TO A PUBLIC CERVICAL CANCER PREVENTION PROGRAM IN EL SALVADOR \u003Csmall\u003E(ID 1040)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1040,"presentation":"INTRODUCING MOBILE COLPOSCOPY TO A PUBLIC CERVICAL CANCER PREVENTION PROGRAM IN EL SALVADOR \u003Csmall\u003E(ID 1040)\u003C\/small\u003E","session":"Oral Session 8: SCREENING IV. Implementation, dissemination, and communication\u00a0","presenter":"Elizabeth Torres (El Salvador)","photo":""},"playlist":[{"name":"INTRODUCING MOBILE COLPOSCOPY TO A PUBLIC CERVICAL CANCER PREVENTION PROGRAM IN EL SALVADOR","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/Elizabeth Torres - IPVC20 Presentation 1040.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/70\/Elizabeth Torres - IPVC20 Presentation 1040.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/3F85C46D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/Elizabeth Torres - IPVC20 Presentation 1040.vtt"}]},{"name":"OROPHARYNGEAL CANCER AND HUMAN PAPILLOMA VIRUS: TIME TO COUNSEL MEDICAL TEAMS \u003Csmall\u003E(ID 479)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":479,"presentation":"OROPHARYNGEAL CANCER AND HUMAN PAPILLOMA VIRUS: TIME TO COUNSEL MEDICAL TEAMS \u003Csmall\u003E(ID 479)\u003C\/small\u003E","session":"Oral Session 8: SCREENING IV. Implementation, dissemination, and communication\u00a0","presenter":"Francis Gilbert (Canada)","photo":""},"playlist":[{"name":"OROPHARYNGEAL CANCER AND HUMAN PAPILLOMA VIRUS: TIME TO COUNSEL MEDICAL TEAMS","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/Francis Gilbert - IPVC20 - 479 - OROPHARYNGEAL CANCER AND HUMAN PAPILLOMA VIRUS TIME TO COUNSEL MEDICAL TEAMS.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/70\/Francis Gilbert - IPVC20 - 479 - OROPHARYNGEAL CANCER AND HUMAN PAPILLOMA VIRUS TIME TO COUNSEL MEDICAL TEAMS.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/29B79C4B.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/Francis Gilbert - IPVC20 - 479 - OROPHARYNGEAL CANCER AND HUMAN PAPILLOMA VIRUS TIME TO COUNSEL MEDICAL TEAMS.vtt"}]},{"name":"LOW AWARENESS AND PERCEIVED RISK FOR HPV AND ASSOCIATED ANAL CANCER AMONG MEN LIVING WITH HIV RECEIVING HIV SPECIALTY CARE IN ONTARIO, CANADA \u003Csmall\u003E(ID 251)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":251,"presentation":"LOW AWARENESS AND PERCEIVED RISK FOR HPV AND ASSOCIATED ANAL CANCER AMONG MEN LIVING WITH HIV RECEIVING HIV SPECIALTY CARE IN ONTARIO, CANADA \u003Csmall\u003E(ID 251)\u003C\/small\u003E","session":"Oral Session 8: SCREENING IV. Implementation, dissemination, and communication\u00a0","presenter":"Jennifer L. Gillis (Canada)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/550.jpg"},"playlist":[{"name":"LOW AWARENESS AND PERCEIVED RISK FOR HPV AND ASSOCIATED ANAL CANCER AMONG MEN LIVING WITH HIV RECEIV","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/GMT20200629-145634_Jennifer-G_1686x768-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/70\/GMT20200629-145634_Jennifer-G_1686x768-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/A47D7277.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/GMT20200629-145634_Jennifer-G_1686x768-0.vtt"}]},{"name":"INCIDENCE RATES FOR OROPHARYNGEAL AND ORAL CAVITY CANCERS AMONG HIV-POSITIVE AND HIV-NEGATIVE INDIVIDUALS IN BRITISH COLUMBIA, CANADA: A RETROSPECTIVE COHORT STUDY \u003Csmall\u003E(ID 433)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":433,"presentation":"INCIDENCE RATES FOR OROPHARYNGEAL AND ORAL CAVITY CANCERS AMONG HIV-POSITIVE AND HIV-NEGATIVE INDIVIDUALS IN BRITISH COLUMBIA, CANADA: A RETROSPECTIVE COHORT STUDY \u003Csmall\u003E(ID 433)\u003C\/small\u003E","session":"Oral Session 8: SCREENING IV. Implementation, dissemination, and communication\u00a0","presenter":"Troy Grennan (Canada)","photo":""},"playlist":[{"name":"INCIDENCE RATES FOR OROPHARYNGEAL AND ORAL CAVITY CANCERS AMONG HIV-POSITIVE AND HIV-NEGATIVE INDIVI","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/GMT20200618-154946_Troy-Grenn_1920x1080.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/70\/GMT20200618-154946_Troy-Grenn_1920x1080.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/515C9DCA.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/GMT20200618-154946_Troy-Grenn_1920x1080.vtt"}]},{"name":"PRELIMINARY RESULTS OF AN ARTIFICIAL INTELLIGENCE CLASSIFIER TO DIAGNOSE CERVICAL PRECANCER \u003Csmall\u003E(ID 858)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":858,"presentation":"PRELIMINARY RESULTS OF AN ARTIFICIAL INTELLIGENCE CLASSIFIER TO DIAGNOSE CERVICAL PRECANCER \u003Csmall\u003E(ID 858)\u003C\/small\u003E","session":"Oral Session 8: SCREENING IV. Implementation, dissemination, and communication\u00a0","presenter":"Miriam Cremer (United States of America)","photo":""},"playlist":[{"name":"PRELIMINARY RESULTS OF AN ARTIFICIAL INTELLIGENCE CLASSIFIER TO DIAGNOSE CERVICAL PRECANCER","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/Miriam Cremer - IPVC20 - Presetation 858.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/70\/Miriam Cremer - IPVC20 - Presetation 858.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/498F0B13.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/Miriam Cremer - IPVC20 - Presetation 858.vtt"}]},{"name":"PERFORMANCE OF THE CAREHPV ASSAY IN GUATEMALA AND HONDURAS \u003Csmall\u003E(ID 1236)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1236,"presentation":"PERFORMANCE OF THE CAREHPV ASSAY IN GUATEMALA AND HONDURAS \u003Csmall\u003E(ID 1236)\u003C\/small\u003E","session":"Oral Session 8: SCREENING IV. Implementation, dissemination, and communication\u00a0","presenter":"Rose Slavkovsky (United States of America)","photo":""},"playlist":[{"name":"PERFORMANCE OF THE CAREHPV ASSAY IN GUATEMALA AND HONDURAS","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/Rose Slavkovsky IPVC20 1236 PERFORMANCE OF THE CAREHPV ASSAY IN GUATEMALA AND HONDURAS.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/70\/Rose Slavkovsky IPVC20 1236 PERFORMANCE OF THE CAREHPV ASSAY IN GUATEMALA AND HONDURAS.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/CC813591.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/70\/Rose Slavkovsky IPVC20 1236 PERFORMANCE OF THE CAREHPV ASSAY IN GUATEMALA AND HONDURAS.vtt"}]}]
{"type":2,"code":"8E32UU02d"}
[session]
[presentation]
[presenter]
